Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome

Evaluation of Efficacy and Safety of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution for the Treatment of Motoric Cognitive Risk Syndrome: A Multi-centre, Randomised, Double Blind and Placebo-controlled Study

This is a multi-centre, randomised, double blind, placebo controlled study on participants with Motoric Cognitive Risk Syndrome to evaluate the efficacy and safety of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution.

Study Overview

• Status: Recruiting
• Conditions: Aging; Mild Cognitive Impairment; Motoric Cognitive Risk Syndrome; Locomotive Syndrome
• Intervention / Treatment: Drug: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution; Drug: Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution

Detailed Description

Cognition and locomotion are two human abilities controlled by the brain. Their decline is highly prevalent with aging, and is greater than the simple sum of their respective prevalence, suggesting a complex age-related interplay between cognition and locomotion.

Recently, a systematic review and meta-analysis has provided evidence that poor gait performance predicts dementia and, in particular, has demonstrated that "motoric cognitive risk" (MCR) syndrome, which has been described in cognitively healthy individuals and combines subjective cognitive complaint with objective slow gait speed, is a pre-dementia syndrome.

MCR as a relatively new recognised clinical syndrome is with a high prevalence calculated around 10% in world population aged 60 and above. MCR syndrome predicts mild and major neurocognitive disorders. MCR syndrome does not rely on a complex and time-consuming assessment, making it applicable to the aging population. Thus, MCR syndrome seems to be a good syndrome to identify individuals at risk of mild and major neurocognitive disorders in any type of healthcare setting.

Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution has proven efficacy for cognitive function deterioration in preliminary studies. The aim of this study is to evaluate its efficacy and safety for MCR.

• Study Type: Interventional
• Enrollment (Anticipated): 800
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Jingjing Li, PhD; Phone Number: +86 ‭13671197166‬; Email: jingjingli0606@126.com

Study Locations

• China
  • Beijing
    • Beijing, Beijing, China, 10010
      • Recruiting
      • Beijing Tiantan Hospital
      • Contact: Jingjing Li, PhD; Phone Number: 13671197166‬; Email: jingjingli0606@126.com
      • Principal Investigator: Jingjing Li, PhD
      • Principal Investigator: Xingquan Zhao, PhD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years to 85 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Sign the informed consent form
• Capability of independent living (capability of dressing, bathing, walking, and bed-chair transfer)
• Met Motoric Cognitive Risk Syndrome (MCR) criteria:

Single task slow gait ( male 60 to 74 y, gait <75.4 cm/s; male ≥ 75 y, gait < 59.1 cm/s; female 60 to 74 y, gait <70.0 cm/s; female ≥ 75 y, gait < 48.3 cm/s) And The Montreal Cognitive Assessment (MoCA) ≤ 26 (≥ 12 education year) or MoCA ≤ 25 (< 12 education year)

• Anticipated good compliance per protocol

Exclusion Criteria:

• Illiteracy
• The Mini-Mental State Examination (MMSE) ≤ 23
• Medical history of mental illness such as schizophrenia, severe anxiety and depression.
• Medical history of Alzheimer's disease, Parkinson's disease, frontotemporal dementia or Huntington's disease.
• Dementia caused by other causes (such as central nervous system trauma, tumor, infection, metabolic disease, normal pressure hydrocephalus, folic acid, vitamin B12 deficiency, thyroid Inferior functions, etc.).
• History of epilepsy, or taking anti-epileptic drugs.
• History of myocardial infarction or stroke
• History of malignant tumor
• Coagulation disorder, systemic bleeding; or previous coagulation disorder or systemic bleeding disease history.
• History of thrombocytopenia or neutropenia.
• History of blood system diseases or liver function abnormalities caused by medication
• Contraindications to ginkgo drugs and a history of known allergies.
• Aphasia, severe hearing or visual impairment, dominant hemiplegia, and other impacts on cognitive evaluation The status of the test.
• Known slow gait causes (non-neurological causes [such as: arthritis, heart disease] and neurological causes [bias Paralysis, ataxia, spasticity, Parkinson's disease and frontal lobe disease])
• Severe heart and lung diseases (coronary heart disease, LVEF<40%, NYHA heart failure grade ≥III, asthma asthma).
• Severe arrhythmia, heart rate >120bpm or <50bpm. (17) Blood pressure <90/60mmHg
• Severe anemia, Hb<100g/L
• Severe liver or renal insufficiency (ALT > 2 times the upper limit of normal or AST > 2 times the upper limit of normal; Creatinine >1.5 times the upper limit of normal)
• Leukopenia (<2×109/l) or thrombocytopenia (<100×109/l)
• Currently enrolled in other drug or medical device study
• Planned any surgery within 6 months at screening
• Considered by investigators as unsuitable participant of this study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Study Arm; Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID	Drug: Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution; TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Study Arm Component: Ginkgo Leaf Extract and Armillariella Mellea Powder, konjac (sweetener), purified water.; Other Names: Yinxingmihuan Koufuyongye
Placebo Comparator: Control Arm; Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution, TID	Drug: Simulation of Ginkgo Leaf Extract and Armillariella Mellea Powder Oral Solution; TID for 6 month after enrolment Glass oral bottle, 10 ml/bottle. Placebo Arm Component: Caramel color (food color), konjac (sweetener), sucrose octaacetate (food additive), sodium benzoate (food additive), purified water.; Other Names: Yinxingmihuan Koufuyongye Moniji

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change of ADAS-Cog	The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) test is one of the most frequently used tests to measure cognition in research studies and clinical trials for new drugs and other interventions.The test administrator adds up points for the errors in each task of the ADAS-Cog for a total score ranging from 0 to 70. The greater the dysfunction, the greater the score. A score of 70 represents the most severe impairment and 0 represents the least impairment.	6 month after enrolment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of Falls	Fall refers to sudden, involuntary, unintentional body position change, falling to the ground or lower plane. Falls include the following two types: (1) falls from one plane to another; (2) falls on the same plane.	6 month after enrolment
Change of each items from ADAS-Cog	The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): A score of 70 represents the most severe impairment and 0 represents the least impairment. The 12 items of ADAS-Cog applied in this study: Word Recall, Commands, Constructional Praxis, Naming, Ideational Praxis, Orientation, Word Recognition, Remembering Word Recognition Test Instructions, Comprehension of Spoken Language, Word-Finding Difficulty, Spoken Language Ability, Concentration/Distractibility	6 month after enrolment
Percentage of change of ADAS-Cog score 4 or more	The Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog): A score of 70 represents the most severe impairment and 0 represents the least impairment. Comparing to baseline, the percentage of ADAS-Cog score decreased 4 or more	6 month after enrolment
TMT-A Score	Trail Making Test (TMT) Parts A & B. Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part A, the circles are numbered 1 - 25, and the patient should draw lines to connect the numbers in ascending order.	6 month after enrolment
TMT-B Score	Trail Making Test (TMT) Parts A & B. Both parts of the Trail Making Test consist of 25 circles distributed over a sheet of paper. In Part B, the circles include both numbers (1 - 13) and letters (A - L); as in Part A, the patient draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letters (i.e., 1-A-2-B-3-C, etc.).	6 month after enrolment
Functional Activities Questionnaire score	Sum scores (range 0-30). Cutpoint of 9 (dependent in 3 or more activities) is recommended to indicate impaired function and possible cognitive impairment.	6 month after enrolment
Activities of Daily Living (ADLs) score	ADL self-performance measures what the resident actually did (not what he or she might be capable of doing) within each ADL category over the prior seven days, according to a performance-based scale. ADL self-performance coding ranges from 0 (independent) to 4 (total dependence) and is coded as 20 items. The total ADL score is a very important component of the RUG categories and is calculated from the seven days immediately preceding and including the date of the assessment. Chang- es, including improvements and declines in function that have occurred since the assessment date are not considered when coding the MDS.	6 month after enrolment
The Neuropsychiatric Inventory Questionnaire	The Neuropsychiatric Inventory-Questionnaire (NPI-Q) was developed and cross- validated with the standard NPI to provide a brief assessment of neuropsychiatric symptomatology in routine clinical practice settings. The NPI-Q is designed to be a self-administered questionnaire completed by informants about patients for whom they care. Each of the 12 NPI-Q domains contains a survey question that reflects cardinal symptoms of that domain.	6 month after enrolment
Dementia Conversion Rate	Defined as conversion rate of MMSE≤23 at 6 month. The Mini-Mental State Examination (MMSE) is a 30-point questionnaire that is used extensively in clinical and research settings to measure cognitive impairment. It is commonly used in medicine and allied health to screen for dementia. It is also used to estimate the severity and progression of cognitive impairment and to follow the course of cognitive changes in an individual over time; thus making it an effective way to document an individual's response to treatment. The MMSE's purpose has been not, on its own, to provide a diagnosis for any particular nosological entity.	6 month after enrolment
Single-task gait speed test	The test can be performed with any patient able to walk 4 metres using the instructions below: Instruct the patient to walk at their normal pace. Patients may use an assistive device, if needed.; Ask the patient to walk down a hallway through a 1-metre zone for acceleration, a central 4- metre "testing" zone, and a 1-metre zone for deceleration (the patient should not start to slow down before the 4-metre mark).; Start the timer with the first footfall after the 0-metre line.; Stop the timer with the first footfall after the 4-metre line.	6 month after enrolment
Dual-task gait speed test-naming animals	For the dual-task trials, participants walked the length of 4 metres while subtracting serial 7s from 100 aloud or while naming animals aloud.	6 month after enrolment

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety endpoints: major cerebral-cardiovascular events	Defined as any non-fatal acute myocardial infarction, non-fatal stroke, cardiovascular death.	6 month after enrolment
Adverse Drug Reaction	An adverse drug reaction is a harmful reaction to a medicine given at the correct dose.	6 month after enrolment

Collaborators and Investigators

• Sponsor: Beijing Tiantan Hospital
• Collaborators: Beijing Stroke Association
• Investigators: Study Chair: Xingquan Zhao, PhD, Department of Neurology, Beijing Tiantan Hospital

Study record dates

Study Major Dates

• Study Start (Actual): July 5, 2021
• Primary Completion (Anticipated): December 31, 2023
• Study Completion (Anticipated): December 31, 2024

Study Registration Dates

• First Submitted: July 27, 2020
• First Submitted That Met QC Criteria: July 27, 2020
• First Posted (Actual): July 30, 2020

Study Record Updates

• Last Update Posted (Actual): December 9, 2021
• Last Update Submitted That Met QC Criteria: December 7, 2021
• Last Verified: December 1, 2021

More Information

Terms related to this study

• Keywords: MCI; MCR; Ginkgo Leaf Extract; Armillariella Mellea Powder
• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Neurocognitive Disorders; Disease; Cognition Disorders; Syndrome; Cognitive Dysfunction; Pharmaceutical Solutions
• Other Study ID Numbers: KY2020-052-03

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No